Evidence map›Paper›PMID 42726372›Full record

ArticleAdvances in therapy2026

Comparing Pneumonia Risks of Budesonide with Fluticasone Among Patients with Asthma in Hong Kong: A Territory-Wide Retrospective Study.

Wang Chun Kwok, Lu Zhou, Ting Fung Ma, Shuk Man Ngai, Raymond Yau Hang Leung, Terence Chi Chun Tam, James Chung Man Ho

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wang Chun Kwok *Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, SAR, 4/F, Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
Lu Zhou *Department of Statistics, University of South Carolina, Columbia, SC, USA.
Ting Fung MaDepartment of Statistics, University of South Carolina, Columbia, SC, USA.
Shuk Man NgaiDepartment of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, SAR, 4/F, Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
Raymond Yau Hang LeungDepartment of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, SAR, 4/F, Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
Terence Chi Chun TamDepartment of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, SAR, 4/F, Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
James Chung Man HoDepartment of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, SAR, 4/F, Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. jhocm@hku.hk.ORCID http://orcid.org/0000-0003-4499-5284

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInterclass difference in pneumonia risks between budesonide (BUD) and fluticasone were not well studied in asthma.

methodsA territory-wide retrospective cohort study was conducted in Hong Kong among adult patients with Global Initiative for Asthma (GINA) step 3 to 5 asthma to examine pneumonia risks among those prescribed BUD or fluticacone (fluticasone furoate (FF) or fluticasone propionate (FP)).

resultsThere were 16,170 patients included with 7169 (44.3%), 7853 (48.6%), and 1148 (7.1%) of them prescribed BUD, FP, and FF, respectively. Using BUD as the reference group, the adjusted odds ratio (aOR), adjusted incidence rate ratio (aIRR), and adjusted hazard ratio (aHR) for all pneumonia events were 0.95 (0.85-1.06, p = 0.32), 1.05 (95% CI 0.99-1.12, p = 0.14), and 0.94 (95% CI 0.86-1.04, p = 0.23) for fluticasone (FF/FP), respectively. The aOR, aIRR, and aHR for hospitalized pneumonia were 0.95 (95% CI 0.84-1.07, p = 0.39), 1.15 (95% CI 0.63-2.08, p = 0.65), and 1.03 (95% CI 0.96-1.16, p = 0.39) for fluticasone (FF/FP). The aOR, aIRR, and aHR for pneumonia requiring ICU admissions were 1.08 (95% CI 0.58-2.00, p = 0.50), 1.15 (95% CI 0.63-2.08, p = 0.65), and 1.06 (95% CI 0.57-1.97 p = 0.85) for fluticasone (FF/FP), respectively. No significant difference in pneumonia risks for BUD and fluticasone (FF/FP) were observed.

conclusionThere was no significant difference in pneumonia risks for BUD and fluticasone (FF/FP) among patients with moderate to severe asthma.

Indexed as

AsthmaBudesonideFluticasone furoateFluticasone propionateInhaled corticosteroidPneumonia

Identifiers

PMID42726372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.